An Update on Anti-Vascular Endothelial Growth Factor Treatment for Retinopathy of Prematurity

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

Nowroozzadeh M. Hossein; Sadeghi Elham; Shahriari Garaee Hossein; Badie Mohammad Reza; Banihashemi Javad; J. Garg Sunir

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: JOURNAL OF CURRENT OPHTHALMOLOGY Year:621 | Volume: | Issue: Page(s): 125-134

Download Full-Text

View:

Download:

Cites:

Information Journal Paper

Title

An Update on Anti-Vascular Endothelial Growth Factor Treatment for Retinopathy of Prematurity

Author(s)

Keywords

AfliberceptQ4

BevacizumabQ4

IntravitrealQ4

RanibizumabQ4

Retinopathy of prematurityQ4

Vascular endothelial growth factorQ4

Abstract

Purpose: To present updated information on the role of anti-Vascular endothelial growth factor (anti-VEGF) therapy for treating Retinopathy of prematurity (ROP). Methods: We searched through PubMed and Scopus databases using the keywords of this article and gathered relevant published articles from the year 2005 to December 2022. The selected articles were classified and summarized, and reasonable conclusions were made accordingly. Results: Considering the current evidence, anti-VEGF agents are superior to laser therapy for the initial treatment of type 1 ROP in zone 1 or posterior zone 2. However, there is a substantial risk of reactivation or persistent avascular retina after solo treatment with anti-VEGFs, and many cases may require laser therapy within the following weeks or months. Thus, vigilant follow-up examinations are mandatory. Conclusions: The role of anti-VEGF agents in the treatment of ROP is indispensable. However, future studies are required to improve indications and dosage and determine long-term ocular and systemic safety.

Cites

No record.

References

No record.

Cite

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops